Digg It
#1 in Business Subscribe Email Print

You are here: Home > Business > Business > Design Risk Assessment In Six Sigma

Tags

  • drugs
  • possible
  • product
  • biological product
  • companies involved

  • Links

  • Considering Health Savings Accounts
  • LG KG800 - Tempting as a Chocolate
  • Most Middle Class Americans Are Slaves!
  • Digg It - Design Risk Assessment In Six Sigma

    The title Design Risk Assessment in Six Sigma beckons to be likened with Poka Yoke or Mistake Proofing. But without going deeper into the comparison part of
    According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
    it, what we can say is that both of these do not have any similarities whatsoever, even though Poka Yoke appears to be the next logical step of Design risk
    ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

    Examples of combination products may in
    Assessment in Six Sigma.

    So What Is Design Risk Assessment In Six Sigma?

    As the name suggests, design risk analysis is the procedure to determine potentia
    lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

    risks in designs and design processes. In Six Sigma, the assessment for design risks is not a ritual that is done at the end but it is an inherent step in
    here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
    he design process itself. It begins from the point of conceptualizing designs where the evaluation exercise continues throughout the designing till the pro
    d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

    Combination pro
    otype is tested.

    The design assessment for potential risks involves design simulation testing at steps including testing the detailed design and sub-assemb
    ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
    ies (subroutines for software, etc) with a view to completely eliminate possible risks and cut down the shocks of design failures. For once, the design risk
    easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
    assessment in Six Sigma goes beyond the CTQ technique providing the design process the much needed broader evaluation.

    Ensuring Reliability Of Design

    The
    nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
    eed for reliability of design can not be overemphasized. The potential hazards of a faulty design extend beyond VOC and ROI parameters. Design risks can not
    and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
    be overlooked even for service offerings even though manufacturing needs to take extra care of this aspect.

    What ensures a systematic and rigorous scrutiny
    ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
    in the dependability of the design also allows capturing system-level hazards.

    Design Risk Assessment Methodologies And Tools

    PHA, Preliminary Hazard Anal
    ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

    Following aspects would a
    ysis is a qualitative assessment of hazards, constituents of the associated functional system and event successions that could potentially result in avoidab
    dd to the challenges in developing combination products:

    Which markets to tap where the combination products can do fairly well?
    Which combination prod
    e consequences. The study includes possible incidents and possible remedial actions. But significantly, this is a qualitative study whose efficacy is applic
    cts are meaningful and rational?
    Which therapeutic categories to select?
    Which Combinations can address unmet needs of the patients?
    Do combin
    ble only for initial studies.

    DFMEA, an implementation methodology, serves as a quantified appraisal of the criticality of internal failures of CTQ & CTC t
    tions increase the patient compliance?
    What would be the developing cost?
    How to tackle the risks encountered during combination product developmen
    gether with performance components. The typical FMEA form may be used also for design assessments and transfers of know-how.

    On the performance front, meet
    t?

    As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
    ng customer expectations infers using CTC's, design parameters which assist meet all of the requirements. It also takes care of the manufacturability requir
    ping new procedures for reviewing their safety, efficacy and quality.

    Professional from academic institutions, pharmaceutical industries, health care indust
    ments. One might think of calling this CTQ.

    The Need For Documentation

    Results of risk analysis tests needs to be documented and then updated as the produ
    y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
    t or service moves in its cycle onto production phase, based on real time failure statistics, which serves as true risk-management and feedback document on
    .

    As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
    esign for future reference.

    The most interesting application of the concept can be found in Bank of Americas assessment for credit products inherent risks
    elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

    Companies that provide selfless information through particip
    hich ultimately helped eliminate potential fraud elements.

    There are multiple instances where FMEA has served as main mast in design and failure evaluation


    tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

    HTTP = HTML link (for blogs, profiles,phorums):
    <a href="http://www.diggit.org.ua/article/2968/diggit-Design-Risk-Assessment-In-Six-Sigma.html">Design Risk Assessment In Six Sigma</a>

    BB link (for phorums):
    [url=http://www.diggit.org.ua/article/2968/diggit-Design-Risk-Assessment-In-Six-Sigma.html]Design Risk Assessment In Six Sigma[/url]

    Related Articles:

    How To Bring Your Personal Brand To Life Through Greeting Cards

    Custom Banners Are Attractive Means For Promotion

    Machiavelli: The Prince - Acquisition Strategy

    Bookmark it: del.icio.us digg.com reddit.com netvouz.com google.com yahoo.com technorati.com furl.net bloglines.com socialdust.com ma.gnolia.com newsvine.com slashdot.org simpy.com shadows.com blinklist.com